LMP1 promotes nasal NK/T-cell lymphoma cell function by eIF4E via NF-κB pathway

Area of Science:

• Oncology
• Virology
• Molecular Biology

Background:

• Nasal natural killer T-cell lymphoma (NKTL) is a rare and aggressive malignancy.
• Epstein-Barr virus (EBV) infection is strongly linked to NKTL pathogenesis.
• Latent membrane protein 1 (LMP1), an EBV-encoded protein, is implicated in EBV-associated cancers.

Purpose of the Study:

• To investigate the role of LMP1 in promoting NKTL progression.
• To elucidate the underlying molecular mechanisms of LMP1's function in NKTL.
• To explore potential therapeutic targets for NKTL.

Main Methods:

• Utilized a human EBV-positive NKTL cell line (SNK-6).
• Employed gene silencing techniques (shRNA) for LMP1 and eukaryotic translation initiation factor 4E (eIF4E).
• Assessed cell proliferation (MTT assay), migration/invasion (Transwell assay), cell cycle, and apoptosis (Flow cytometry).

Main Results:

• LMP1 was highly expressed in SNK-6 cells.
• LMP1 silencing inhibited proliferation, induced G0/G1 phase arrest, reduced migration and invasion, and promoted apoptosis.
• LMP1 overexpression upregulated eIF4E, and eIF4E inhibition reversed LMP1-induced effects.
• LMP1's effect on eIF4E was mediated by the NF-κB pathway.

Conclusions:

• LMP1 significantly promotes NKTL progression by upregulating eIF4E expression via the NF-κB pathway.
• Targeting LMP1 or eIF4E presents a potential therapeutic strategy for EBV-positive NKTL.